跳至主要内容
临床试验/NCT02002585
NCT02002585Unknown2 期

Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease (Kidney Protection Study - KPS Study)

Charles University, Czech Republic2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2013年11月1日最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
60
试验地点
2
主要终点
Changes in the value of Cystatin C

研究概览

简要总结

Kidney protection study (KPS 1) is a prospective randomized clinical study comparing the use of renal denervation (RDN) and optimal medical therapy in subjects with chronic kidney disease stage 3-4 and resistant arterial hypertension to optimal medical therapy alone. Renal denervation is a modern endovascular method used to treat resistant hypertension. The method is being extended to other groups of patients, where the sympathetic tone is increased beyond resistant hypertension. Because of the character of the disease, we hypothesize that renal denervation can reduce or prevent progressive deterioration of kidney functions in this patient population. The aim of this clinical study is to show that renal denervation has protective effects on the progression of chronic renal insufficiency.

详细描述

Background:

patients with chronic renal insufficiency are an ideal group for renal denervation (RDN), because of the increase in sympathetic tone. This increase leads to sodium retention, reduction of perfusion of the kidney and to excessive activation of renin angiotensin aldosterone system. The activation of the sympathetic system significantly contributes to the progression of chronic renal insufficiency. The consequences the hyperactivity of the sympathetic system are affected by selective renal sympathectomy. RDN demonstrably reduces retention of sodium, reduces the production of renin and significantly reduces renal vascular resistance. Furthermore, RDN reduces microalbuminuria and renal podocyte damage in experimental model. RDN also improves renal function in the model of acute Glomerulonephritis. In patients with resistant hypertension and preserved renal function, it was also shown that renal denervation improves renal resistant index and significantly decreases microalbuminuria. The procedure was found to be safe in all studies with renal denervation and was not associated with deterioration of renal function. Several experimental data exist on the effectiveness of RDN in chronic renal insufficiency. In a model of acute renal failure in mouse (endotoxemia model), it was shown that RDN has protective effect on renal function. The decline in the glomerular filtration during endotoxemia was significantly lower in the group treated with RDN compared to the control group. In addition, the renal flow during acute renal failure after RDN was improved. In the model of heart failure in mice, it has been shown that RDN in combination with olmesartan reduces albuminuria and the damage of podocytes and also reduces the levels of renal norepinephrine, angiotensinogen, angiotensin II, and the level of oxidative stress.

Very few data on the effect of RDN on renal function in human were also published. Renal damage in hypertensives subject was not found after RDN with the Symplicity system more than 3 years post procedure. Mahfoud and coworkers showed that subject treated with RDN had lower blood pressure and renal resistive index and at the same time stabilize their renal function. The number of patients with microalbuminuria or macroalbuminuria decreased significantly one year after RDN.

RDN has also positive effect on albuminuria and proteinuria in patients with preserved renal function. The first studies performed in patients with chronic kidney disease (CKD stage 3-4) and resistant hypertension was done by Hering et coworkers. In this study, 15 patients with an average eGFR of 31ml/min/1, 73m2 underwent RDN. The authors were able to show that RDN effectively lowers blood pressure and was not associated further deterioration of renal function. RDN had other positive effects on hemoglobin concentration , proteinuria and on BNP levels. Moreover, the augmentation index of peripheral arteries was also improved by RDN. This work showed multiple effects of RDN beyond the reduction of blood pressure. We, therefore think that patient with chronic kidney disease are good candidates for RDN. However, the mentioned study has a relatively short term follow up (6 months to one year) and does not have a comparative arm.

Aim of study :

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent
  • Age between 18-80 years
  • Chronic renal insufficiency in CKD 3-4 from nephrologist (eGFR (MDRD) ≤ 45 ml/min/1.73 m2)
  • Arterial hypertension treated with:
  • systolic BP ≥ 140 mmHg + at least 3 antihypertensive drugs Including a diuretic systolic BP ≥ 135 mmHg + 3 antihypertensives Including a diuretics + diabetes mellitus type
  • systolic BP ≥ 130 mmHg on 24 hr ABPM + 3 antihypertensive drugs Including a diuretics
  • Renal artery diameter ≥ 4 mm according to the renal angiography (documented on quantitative renal angiography), renal artery length at least 20mm

排除标准

  • Secondary hypertension
  • White coat hypertension
  • abnormalities in renal angiogram disqualifying for RDN
  • Life expectancy < 1 year
  • Diabetes mellitus
  • Significant stenotic valvular heart disease
  • Acute coronary syndrome of unstable angina in the past 6 months

结局指标

主要结局

Changes in the value of Cystatin C

时间窗: 6 months

Changes in the value of Cystatin C measure at baseline and after 6 months in both groups

The changes of eGFR by MDRD

时间窗: 6 months

The changes of the value of eGFR measured using the MDRD equation in both groups measure at baseline and after 6 months

Changes in proteinuria (Microalbuminuria) in 6 months

时间窗: 6 months

the change in the value of proteinuria expressed in g/24hrs or microalbuminuria expressed in ug/24hrs measured at baseline compared to value at 6 month in both study groups

Time to the development of end-stage renal disease (ESRD)/Hemodialysis

时间窗: 3 years

The time to the development of end-stage renal disease (ESRD)/Hemodialysis in both groups

combined renal endpoint

时间窗: 6 months

the combination of all primary outcomes measured compared to baseline in both groups

次要结局

  • Total mortality(3 years)
  • The total cardiovascular mortality(3 years)
  • total renal mortality(3 years)
  • changes in blood pressure(3 years)
  • •Changes in concentration of Blood urea Nitrogen (BUN) , creatinine in 6 months, 3 years(3 years)
  • albumin-creatine ratio(3 years)
  • changes in cardiac structure and function(3 years)
  • the changes in renal resistive index(3 years)

研究者

发起方
Charles University, Czech Republic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ass. prof. Jean-Claude M. Lubanda, MD, Ph.D

Associate professor

Charles University, Czech Republic

研究点 (2)

Loading locations...

相似试验